Skip to content

Effect of different drug intervention on emergency agitation during recovery period of laparoscopic surgery in children

Effect of different drug intervention on emergency agitation during recovery period of laparoscopic surgery in children

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066542
Enrollment
Unknown
Registered
2022-12-08
Start date
2022-12-14
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergence agitation in children

Interventions

Dexmedetomidine group:Dextrmedetomidine 1ug/kg intravenous infusion
Esketamine group:Esketamine 0.3mg/kg intravenously

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 7 Years

Inclusion criteria

Inclusion criteria: 1. ASA I or II; 2. Children aged from 1 to 7 years who need laparoscopic surgery for endotracheal intubation and general anesthesia; 3. There was no obvious disease of heart, liver, kidney or nervous system before operation.

Exclusion criteria

Exclusion criteria: 1. Allergic to dexmedetomidine, esketamine and other drugs; 2. Children with congenital heart disease, asthma, mental diseases and other diseases; 3. History of respiratory tract infection 1 week before surgery; 4. Preoperative liver and/or renal dysfunction; 5. Long-term use of sedative or analgesic drugs.

Design outcomes

Primary

MeasureTime frame
5-point Agitation Scale;Face, Legs, Activity, Crying, Consolability Score for pain;Pediatric Anesthesia Emergence Delirium Scale;

Secondary

MeasureTime frame
Heart rate;Mean arterial pressure;Pulse oxygen saturation;

Countries

China

Contacts

Public ContactLin Yu'nan

The First Affiliated Hospital of Guangxi Medical University

2277464077@qq.com+86 13768278751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026